LifeTech Scientific Completes Follow-up of Phase 2 Clinical Study of IBS Coronary Scaffold

LifeTech Scientific (HKG:1302) successfully completed its self-developed IBS Coronary Scaffold's one-year follow-up of the phase II clinical study, according to a filing with the Hong Kong Exchange on

MT NewswiresMay 16 06:05 ET

Xianjian Technology: Announcing the one-year follow-up results of the IBS absorbable drug-eluting coronary stent system phase II clinical study

Xianjian Technology (01302) announced that the IBS absorbable drug-eluting coronary stent system (IBS coronary stent) independently developed by the group has successfully completed a one-year follow-up phase II clinical study, and on May 14, 2024, Director Song Lei of Fuwai Hospital of the Chinese Academy of Medical Sciences represented Academician Gao Runlin and all researchers for the first time at the 2024 European Interventional Cardiology Conference (EuroPCR 2024). The IBS coronary stent phase II clinical study is a prospective, multicenter, single-blind, randomized controlled clinical study. The main end point of the study was two years after coronary stent implantation

新浪港股May 15 20:29 ET

Xianjian Technology (01302): Announcing the one-year follow-up results of the IBS absorbable drug-eluting coronary stent system phase II clinical study

Xianjian Technology (01302) issued an announcement that IBS independently developed by the group can absorb...

Zhitong FinanceMay 15 06:44 ET

Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points

The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.

Zhitong FinanceMay 13 02:57 ET

Positive Earnings Growth Hasn't Been Enough to Get LifeTech Scientific (HKG:1302) Shareholders a Favorable Return Over the Last Three Years

If you love investing in stocks you're bound to buy some losers. Long term LifeTech Scientific Corporation (HKG:1302) shareholders know that all too well, since the share price is down considerably o

Simply Wall StMay 2 19:43 ET

先健科技：2023年度報告

Futu NewsApr 18 04:37 ET · Announcements